Audit: QRS - Sh-Polypeptide-11 for Hair Regrowth
Audit conducted on 28/06/2026 01:56 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 86 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER (mechanism, benefits, risks, protocol, monitoring). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “no published human studies”, “theoretical”, “speculative” framing preserved. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications and cautious benefit framing carried at same strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories preserved; contraindications and interactions drawn from the correct ER section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCTs, expert names, or brand names introduced in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Cautious, evidence-graded tone consistent with the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Balanced expert-but-accessible tone throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents information, no prescriptive directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advice-style phrasing; footer disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Descriptive phrasing used throughout. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language with minimal jargon. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cards and bulleted items. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct reader address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing matches a proactive, risk-aware audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring detail assumes a willing, engaged reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth exceeds general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | “early-stage add-on” weighting fits the audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” language present. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register maintained (e.g., “local skin reactions”, “microcirculation”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings/labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present; repeatable marker/qualitative patterns correctly expanded. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Non-addressed spans unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No empty sections required; populated sections all have ER-derived content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Tier labels and marker labels match ER. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels retained as in ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in the QRS body. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to a single-page layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after doctype (lines 2-14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only “duration” is quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: sh_polypeptide_11_hair_2026-0628-0047_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.5.18 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0628-0047 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 4.8” = nickname + version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: sh_polypeptide_11_hair_2026-0628-0047_Opus_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Frontmatter clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Sh-Polypeptide-11 for Hair Regrowth - Quick Reference Sheet” (line 22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Sh-Polypeptide-11 for Hair Regrowth” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 06/28/2026 from 2026-0628 (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8” (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distills the Conclusion (plausible mechanism, no human proof, delivery, tolerability, add-on). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each claim maps to the Conclusion section. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain language; “add-on” not “adjunct”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trials cited. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No statistics cited. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from “Populations who should avoid it” (ER line 229). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four avoidance populations represented. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> items (lines 542-545). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise; no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | “at the site”, “in the treatment area”, “active or recent” qualifiers preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation present; items are plain lists. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER interactions bullets (lines 219-227). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Five interaction items; no contraindication overlap. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Five <li> items (lines 553-557). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise; no trailing clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | Example drug lists (tretinoin, adapalene; glycolic, salicylic; sh-Polypeptide-1/bFGF, copper tripeptide) preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation present. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Key Interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Actions trace to the Therapeutic Protocol section. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Application, Delivery, Best Use cover the key actionable aspects. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects available and used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated from the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Earliest change, ~12 weeks, ~24 weeks derived from Practical Considerations. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered earliest-to-fuller assessment. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three time aspects available and used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All three time cells populated from the ER. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the four Speculative benefit sub-items. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present; only speculative populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise semicolon-separated list. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Increased Density)” and “(Anagen)” parentheticals stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | high/medium/low spans set to display:none. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from Low and Speculative risk items. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present; low and speculative populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise items. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Irritation, Redness, Itching)” parenthetical stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | high/medium spans set to display:none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Biomarker table derived from the ER Monitoring Protocol table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All five (Ferritin, TSH, Vitamin D, Total testosterone & DHEA-S, Zinc) listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated (baseline once, re-test if indicated; assessment at baseline/12/24 weeks/6 months). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Qualitative items drawn from the ER qualitative markers. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four qualitative markers listed. |
Issues 28/06/2026 01:56
Pass rate 100.00%. No issues found.
Issues 28/06/2026 01:52
- 12.4 — Benefit parenthetical not stripped: The ER benefit heading “Stimulation of Hair Regrowth (Increased Density)” had its parenthetical preserved as “Stimulation of hair regrowth and increased density” in benefits_speculative (line 531); it must be stripped.
- 13.4 — Risk parenthetical not stripped: risks_low keeps the ER heading parenthetical as “Local skin reactions (irritation, redness, itching)” (line 576); the “(irritation, redness, itching)” must be stripped.
Fixes 28/06/2026 01:52
- 12.4 — Benefit parenthetical stripped: Changed benefits_speculative from “Stimulation of hair regrowth and increased density” to “Stimulation of hair regrowth”, removing the carried-over “(Increased Density)” parenthetical.
- 13.4 — Risk parenthetical stripped: Changed risks_low from “Local skin reactions (irritation, redness, itching)” to “Local skin reactions”, removing the parenthetical.
Issues 28/06/2026 01:48
- 11.1 — Time cells not three distinct aspects: time_1 “Minimum Trial ~3 months” and time_2 “First Assessment ~12 weeks” restate the same ER point (results judged no earlier than ~3 months / first meaningful assessment ~12 weeks, line 298), so the three cells do not represent three distinct time-to-effect aspects.
Fixes 28/06/2026 01:48
- 11.1 — Distinct time-to-effect aspects: Replaced the redundant first cell (“Minimum Trial / ~3 months”, which duplicated the ~12-week First Assessment) with a distinct ER-supported aspect: “Earliest Visible Change / Months, not weeks / Hair cycles are slow; not to be judged before about three months” (ER line 298), so the three cells now cover three distinct horizons.
Issues 28/06/2026 01:44
- 11.2 — Time cells not ordered by benefit magnitude: The three Time-to-Effect cells (First Assessment ~12 weeks, Fuller Assessment ~24 weeks, Minimum Trial ~3 months; QRS lines 483-512) are assessment milestones for a single benefit cluster, so they cannot be picked/ordered by related-benefit magnitude as required; “Minimum Trial ~3 months” sits after “First Assessment ~12 weeks” despite being the same/earlier time point.
Fixes 28/06/2026 01:44
- 11.2 — Time cells ordered by magnitude: Reordered the three Time-to-Effect cells into a sensible time progression — Minimum Trial (~3 months) first, then First Assessment (~12 weeks), then Fuller Assessment (~24 weeks) — so the earliest meaningful-result threshold leads instead of trailing the 12-week cell.